Aspen Aerogels, Inc. $ASPN Shares Sold by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Aspen Aerogels by 11.3% during the first quarter, holding approximately $3.12 million in shares after selling 61,978 shares.
• Aspen Aerogels recently reported a loss of ($0.04) earnings per share for the quarter, surpassing the consensus estimate, while also experiencing a 33.8% decrease in revenue compared to the previous year.
• Research analysts have shown mixed views on the stock; Barclays downgraded it to "underweight," while others maintain a "buy" rating, leading to a current consensus rating of "Moderate Buy."

Charles Schwab Investment Management Inc. decreased its stake in Aspen Aerogels, Inc. (NYSE:ASPN - Free Report) by 11.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 487,731 shares of the construction company's stock after selling 61,978 shares during the period. Charles Schwab Investment Management Inc. owned 0.59% of Aspen Aerogels worth $3,117,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Banque Cantonale Vaudoise bought a new stake in shares of Aspen Aerogels in the 1st quarter worth approximately $45,000. Exchange Traded Concepts LLC lifted its holdings in shares of Aspen Aerogels by 460.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 7,436 shares of the construction company's stock worth $48,000 after purchasing an additional 6,109 shares during the last quarter. CWM LLC lifted its holdings in shares of Aspen Aerogels by 2,137.9% in the 1st quarter. CWM LLC now owns 8,325 shares of the construction company's stock worth $53,000 after purchasing an additional 7,953 shares during the last quarter. Teacher Retirement System of Texas acquired a new stake in Aspen Aerogels in the 1st quarter valued at approximately $65,000. Finally, Sandia Investment Management LP acquired a new stake in Aspen Aerogels in the 4th quarter valued at approximately $89,000. Institutional investors own 97.64% of the company's stock.

Aspen Aerogels Price Performance

Shares of ASPN stock traded down $0.13 during mid-day trading on Monday, hitting $6.83. 1,079,251 shares of the stock traded hands, compared to its average volume of 2,428,220. Aspen Aerogels, Inc. has a twelve month low of $4.16 and a twelve month high of $30.24. The firm has a market cap of $562.52 million, a price-to-earnings ratio of -1.79 and a beta of 2.65. The company's 50-day simple moving average is $7.03 and its 200-day simple moving average is $6.56. The company has a debt-to-equity ratio of 0.34, a quick ratio of 3.31 and a current ratio of 3.98.

Aspen Aerogels (NYSE:ASPN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The construction company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.08. Aspen Aerogels had a positive return on equity of 2.92% and a negative net margin of 78.53%.The company had revenue of $78.02 million for the quarter, compared to analysts' expectations of $72.53 million. During the same period last year, the firm earned $0.21 EPS. The firm's revenue for the quarter was down 33.8% on a year-over-year basis. Aspen Aerogels has set its FY 2025 guidance at -3.860--3.730 EPS. As a group, equities research analysts expect that Aspen Aerogels, Inc. will post 0.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ASPN has been the topic of several analyst reports. Oppenheimer cut Aspen Aerogels from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 8th. Barclays cut Aspen Aerogels from an "equal weight" rating to an "underweight" rating and raised their target price for the company from $7.00 to $16.00 in a research report on Monday, August 11th. Finally, Canaccord Genuity Group lowered their target price on Aspen Aerogels from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $19.50.

Insider Activity

In related news, CAO Santhosh P. Daniel sold 4,410 shares of Aspen Aerogels stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $7.31, for a total value of $32,237.10. Following the transaction, the chief accounting officer directly owned 19,879 shares in the company, valued at $145,315.49. The trade was a 18.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 3.40% of the stock is owned by insiders.

Aspen Aerogels Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.